MedTrace Logo

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

NCT03846427 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2024-10-26

Study results available
· View outcomes & findings →

Summary

This is a single arm study to evaluate the efficacy, safety and tolerability of zanubrutinib (BGB-3111) in participants with relapsed/refractory marginal zone lymphoma (R/R MZL).

Conditions

Interventions

DRUG

Zanubrutinib

Zanubrutinib at a dose of 160 mg orally twice a day (BID)

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Principal Investigators

  • Study Director · BeiGene

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-19
Primary Completion
2022-05-04
Completion
2022-05-04
FDA Drug
Yes

Countries

  • United States
  • Australia
  • China
  • Czechia
  • France
  • Italy
  • New Zealand
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03846427 on ClinicalTrials.gov